ABSTRACT
Introduction: Glioblastoma Multiforme [WHO grade IV glioma] still remains a dreadful diagnosis in oncology with the median survival ranging between 12 to 17 months, despite the recent advances in its management[11,12] It is the most common malignant primary tumour in adults[13]. The standard of care is Maximal Safe Resection followed by Concomitant ChemoRadiotherapy
Methods: During the period 2006 to 2010 at Radium Institute, Patna Medical College and Hospital [PMCH] in India, a study was conducted on 37 newly diagnosed GBM cases in which the control-arm [c-arm] received Conventional Radiotherapy [60Gy/30 number] only whereas the study arm [s-arm] received Concomitant Chemoradiotherapy followed by Adjuvant Temozolomide
Results: The median survival was 15.4 months in the s-arm as compared to 12.4 months in the c-arm. The OS showed a significant improvement with p-value of 0.05 and PFS also showed a benefit with a p-value of 0.005
Conclusion: The results were encouraging with improvement in OS as well as PFS in the s-arm and were at par with the other similar studies conducted in different parts of the world